Biomedical Research Foundation Academy Of AthensAcademy Of Athens
Scientific Personnel

Constantin Constantin Tamvakopoulos, PhD
Investigator - Professor Level

Telephone : +30 210 6597475
e-mail :

Center :

Clinical, Experimental Surgery & Translational Research

Lab Site :

Tamvakopoulos Lab

Brief Bio

Dr. Constantin Tamvakopoulos received his B.A. in Chemistry from the University of Chicago in 1986. He continued his studies in the United States and received a Ph.D. in Chemistry/Biochemistry from Brown University in 1992. Following his graduate studies he joined the department of Pharmacokinetics and Drug Metabolism at Purdue Pharma LP (a private pharmaceutical company specializing in drug delivery forms) as a Senior Scientist and then as a Principal Scientist in the same department until 1997. From 1997 until 2004 he held positions at Merck Research Laboratories as a Senior Research Chemist and a Research Fellow in the department of Basic Chemistry. In 2004 he accepted a tenure track position at the Department of Pharmacology, Biomedical Research Foundation of the Academy of Athens and he currently holds the position of Investigator - Professor level in the same division.

Dr. Tamvakopoulos' main focus of research revolves around the development of targeted therapeutics, discovery of translational biomarkers and application of novel mass spectrometric techniques with significance in biomedical research. By placing emphasis on pharmacokinetic and drug metabolism questions, pharmacologic action can be better understood with beneficial consequences to the design of future therapies. He is particularly interested in anti-cancer cytotoxic targeted therapeutics, as well as anti-angiogenesis therapeutic molecules.

Some of his main scientific contributions as a graduate student at Brown included the development of novel mass spectrometric approaches for the quantification of the intermediates of fatty acid metabolism. The methodology was applied towards the establishment of Acyl-CoA profiles in patient fibroblasts with inherited metabolic diseases, in collaborative studies with the Children's Hospital in the University of Pennsylvania.

At Merck Research Laboratories, Dr. Tamvakopoulos collaborated with synthetic chemists, biologists, pharmacologists in many new drug discovery programs in the therapeutic areas of metabolic disorders (obesity, diabetes), inflammation (arthritis) and atherosclerosis and actively participated towards the advancement of new leads in the various drug discovery programs. Some of those leads have now advanced to phases of clinical development by Merck or have received approval as treatments (e.g. JanuviaTD).

Dr Tamvakopoulos currently finds himself in a stimulating research environment at BRFAA which generates new opportunities for collaborations in projects that could lead to compounds with potential as anti-cancer drugs or chemopreventive agents, with particular emphasis on targeted therapies. He has over 60 publications in peer-reviewed journals, has served as a member of the scientific advisory board of the national regulatory agency for new drug approvals (EOF), as a peer reviewer on the Danish Research Council, and has been a PI or Co-PI in several grants related to his research interests (listed below).  Finally he is a co-inventor of a recently filled patent on the application of an anti-Myc compound for pancreatic cancer.

Representative grants over the past few years with Associate Professor C. Tamvakopoulos as a principal Investigator (PI) or a co-PI

Selected Publications

Orestis Argyros, Theodoros Karampelas, Xenophon Asvos, Aimilia Varela, Nisar Sayyad, Athanasios Papakyriakou, Constantinos H Davos, Andreas G Tzakos, Demosthenes Fokas, and Constantin Tamvakopoulos. Peptide-drug conjugate GnRH-sunitinib targets angiogenesis selectively at the site of action to inhibit tumor growth. Cancer Res canres.2138.2015; Published OnlineFirst December 8, 2015; doi:10.1158/0008-5472.CAN-15-2138

Stellas D, Szabolcs M, Koul S, Li Z, Polyzos A, Anagnostopoulos C, Cournia Z, Tamvakopoulos C, Klinakis A, Efstratiadis A. (2014) Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer J Natl Cancer Inst. 2014 Oct 11;106(12)

Karampelas T, Argyros O, Sayyad N, Spyridaki K, Pappas C, Morgan K, Kolios G, Millar RP, Liapakis G, Tzakos AG, Fokas D, Tamvakopoulos C.  (2014) GnRH-Gemcitabine Conjugates for the Treatment of Androgen-Independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery.  Bioconjug Chem. 16;25(4):813-23.

Koltsida O, Karamnov S, Pyrillou K, Vickery T, Chairakaki A-K, Tamvakopoulos C, Sideras P, Serhan CN, Andreakos E (2013) Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation EMBO Mol Med. ;5(5):762-75

Chatziioannou AN, Siskos AP, Loxas D, Kavatzas, N, Agrogiannis G, Fokas D, Malagari K, Kostomitsopoulos N, Tsigkou O, Tamvakopoulos C (2013) Transarterial Embolization with Sorafenib in animal livers: a pharmacokinetic study. J Vasc Interv Radiol. ;24(11):1657-63

Katsila T, Balafas E, Liapakis G, Limonta P, Montagnani Marelli M, Gkountelias K, Tselios T, Kostomitsopoulos N, Matsoukas J, and Tamvakopoulos C (2011) Evaluation of a stable gonadotropin releasing hormone analogue in mice for the treatment of endocrine disorders and prostate cancer.  J Pharmacol Exp Ther. 336 (3):613-23

Siskos AP, Katsila T, Balafas E, Kostomitsopoulos N, Tamvakopoulos C (2009) Simultaneous Absolute Quantification of the Glucose-Dependent Insulinotropic Polypeptides GIP1-42 and GIP3-42 in Mouse Plasma by LC/ESI-MS/MS: Preclinical Evaluation of DP-IV Inhibitors. J Proteome Res., 8 (7):3487-96.

Garbis SD, Tyritzis SI, Roumeliotis T, Zerefos P, Giannopoulou EG, Vlahou A, Kossida S, Diaz J, Vourekas S, Tamvakopoulos C, Pavlakis K, Sanoudou D, Constantinides CA. (2008) Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res. Aug;7(8):3146-58.

Z.D. Sofianos, T. Katsila, N. Kostomitsopoulos, V. Balafas, J. Matsoukas, T. Tselios, and C. Tamvakopoulos (2008) In vivo evaluation and in vitro metabolism of leuprolide in mice—mass spectrometry-based biomarker measurement for efficacy and toxicity J. Mass Spectrom, 43: 1381-1392.

Tamvakopoulos C, Dimas K, Sofianos ZD, Hatziantoniou S, Han Z, Liu ZL, Wyche JH, Pantazis P (2007). Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res. 13(4):1269-77.

Tamvakopoulos C. (2007) Mass spectrometry for the quantification of bioactive peptides in biological fluids. Mass Spectrom Reviews, 26 (3): 389-402.

Van der Ploeg LH, Martin WJ, Howard AD, Nargund RP, Austin CP, Guan X, Drisko J, Cashen D, Sebhat I, Patchett AA, Figueroa DJ, DiLella AG, Connolly BM, Weinberg DH, Tan CP, Palyha OC, Pong SS, MacNeil T, Rosenblum C, Vongs A, Tang R, Yu H, Sailer AW, Fong TM, Huang C, Tota MR, Chang RS, Stearns R, Tamvakopoulos C, Christ G, Drazen DL, Spar BD, Nelson RJ, MacIntyre DE. (2002) A role for the melanocortin 4 receptor in sexual function.  Proc Natl Acad Sci U S A. – 99(17), 11381-11386.


PubMed Link